Advertisement Pluristem announces milestone in build-out of new PLX cells cGMP facility - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Pluristem announces milestone in build-out of new PLX cells cGMP facility

Pluristem Therapeutics has achieved milestone towards completion of its new good manufacturing process (cGMP) manufacturing facility for placental eXpanded (PLX) cells in Haifa, Israel.

For the completion, the company has initiated the installation qualification (IQ) validation process through Biopharmax Group, which is handling the build-out of Pluristem’s facility.

Following the successful IQ, an operation qualification (OQ) will be initiated, which marks the final stage of the build-out process.

Once constructed, the new facility will produce commercial grade PLX cells which will complement Pluristem’s current 40,000ft² manufacturing facility.

Pluristem chairman and CEO Zami Aberman said, "We are extremely pleased with the progress of erecting one of the most technological advanced commercial grade cell manufacturing facility in the world."